Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

De Lorenzo, Claudia; Paciello, Rolando; Riccio, Gennaro; Rea, Domenica; Barbieri, Antonio; Coppola, Carmela; Maurea, Nicola.

Afiliação

De Lorenzo C; Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy.
Paciello R; Ceinge, Biotecnologie Avanzate s.c.a.r.l., Naples, Italy.
Riccio G; Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, Italy.
Rea D; Ceinge, Biotecnologie Avanzate s.c.a.r.l., Naples, Italy.
Barbieri A; Department of Pharmacy, Federico II University, Naples, Italy.
Coppola C; Division of Cardiology, Istituto Nazionale Tumori - Irccs Fondazione G. Pascale, Naples, Italy.
Maurea N; Division of Cardiology, Istituto Nazionale Tumori - Irccs Fondazione G. Pascale, Naples, Italy.

Onco Targets Ther ; 11: 2241-2250, 2018.

Article em En | MEDLINE | ID: mdl-29719406